MHC class I-presented tumor-associated antigen peptides (on autologous dendritic cell–tumor cell hybrids) (DC-tumor fusion (DCTF))

MHC class I-presented tumor-associated antigen (TAA) peptides on autologous dendritic cell–tumor cell hybrids represent a sophisticated target for personalized cancer immunotherapy. This approach involves the physical fusion of a patient's own dendritic cells (DCs)—the most potent antigen-presenting cells—with their own inactivated tumor cells to create a hybridoma (Gong et al., 2000, Nature Medicine). These hybrid cells integrate the antigen-processing machinery of the DC with the full spectrum of antigens from the tumor cell, including shared TAAs and unique neoantigens. Consequently, the hybrids present these peptides via MHC class I and II pathways in the presence of essential costimulatory molecules like CD80 and CD86, which are provided by the DC partner (Koido et al., 2013, Vaccines). This presentation effectively primes both CD8+ cytotoxic T lymphocytes and CD4+ helper T cells, leading to a robust, polyclonal anti-tumor immune response. Clinical studies have explored this target in various malignancies, including renal cell carcinoma and breast cancer, often demonstrating the induction of tumor-specific T-cell responses and occasional clinical regressions (Avigan et al., 2004, Clinical Cancer Research). The primary therapeutic challenge lies in the logistical complexity of creating autologous fusions and the potential for the tumor microenvironment to suppress the newly generated immune response.

Other names

Dendritic cell-tumor cell hybridsDC-tumor fusion cellsAutologous DC-tumor fusion vaccineHybridoma cancer vaccineDC-tumor cell fusion

Presentation of a broad spectrum of tumor-associated antigens and neoantigens via MHC class I and II molecules to prime and activate a polyclonal T-cell response.